Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN)

Connor Clark & Lunn Investment Management Ltd. grew its stake in Compugen Ltd. (NASDAQ:CGEN) by 82.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 274,335 shares of the biotechnology company’s stock after buying an additional 124,190 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.31% of Compugen worth $497,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CGEN. Rothschild Investment LLC purchased a new stake in Compugen in the 2nd quarter worth approximately $380,000. ARK Investment Management LLC increased its position in shares of Compugen by 4.7% during the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after purchasing an additional 48,979 shares during the last quarter. Secure Asset Management LLC bought a new stake in Compugen in the second quarter worth $69,000. Joel Isaacson & Co. LLC boosted its stake in Compugen by 136.4% during the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock worth $94,000 after buying an additional 30,000 shares during the period. Finally, Squarepoint Ops LLC increased its position in Compugen by 23.4% during the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 16,253 shares during the last quarter. Institutional investors own 12.22% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

Compugen Stock Performance

Shares of NASDAQ CGEN opened at $1.59 on Friday. Compugen Ltd. has a fifty-two week low of $0.65 and a fifty-two week high of $3.03. The company has a market cap of $141.89 million, a price-to-earnings ratio of 80.50 and a beta of 2.64. The business’s 50 day moving average price is $1.67 and its 200-day moving average price is $1.83.

Compugen (NASDAQ:CGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.20). The business had revenue of $17.13 million for the quarter, compared to the consensus estimate of $17.67 million. Compugen had a return on equity of 2.62% and a net margin of 2.67%. During the same quarter last year, the business posted ($0.11) earnings per share. Sell-side analysts predict that Compugen Ltd. will post 0.11 earnings per share for the current year.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.